Wait a sec... is this the same guy?
Furthermore OXIS most recently announced that it executed definitive agreements licensing certain assets for the treatment of Multiple Myeloma and initiated a consulting agreement with University of Pittsburgh’s Professor, Dr. Xiang-Qun(Sean)Xie (one of the world’s foremost cannabinoid research scientists). The American Cancer Society’s estimates for multiple myeloma in the United States for 2015 are about 26,850 new cases of multiple myeloma and about 11,240 deaths from multiple myeloma alone.
The license agreement provides Oxis Biotech, Inc an exclusive worldwide license to develop and commercialize therapies for the treatment of Multiple Myeloma (a type of cancer that attacks plasma cells in bone marrow). Dr. Xie joins Oxis Biotech as a consultant and member of the Science Advisory Board to further develop the assets licensed to Oxis Biotech, Inc. Among the mile-long track record of amazing accomplishments that Dr. Xie holds (See below), he is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.
Mr. Cataldo stated, “I wanted to leverage Dr. Xie’s significant experience and technologies, much the same way I did when I acquired highly valued patents from the NCI (NIH) for stage 4 Melanoma from the National Cancer Institute to form Lion Biotechnologies, Inc. (LBIO)”.
In addition to this, University of Pittsburgh’s new Chancellor Patrick Gallagher encourages industry partnership of the University with OXIS. This will further enhance the overall R & D capabilities of the company and could propel the company’s growth by leaps and bounds just as the case was for market leaders like GW Pharma.
